Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3.

PloS one - 1 Jan 2014

Niederau Claus, Mauss Stefan, Schober Andreas, Stoehr Albrecht, Zimmermann Tim, Waizmann Michael, Moog Gero, Pape Stefan, Weber Bernd, Isernhagen Konrad, Sandow Petra, Bokemeyer Bernd, Alshuth Ulrich, Steffens Hermann, Hüppe Dietrich

Abstract excerpt

BACKGROUND: Previous trials have often defined genotype 2 and 3 patients as an "easy to treat" group and guidelines recommend similar management. AIMS: The present study looks for differences between the two genotypes and analyzes predictive factors for SVR. METHODS: Prospective, community-based cohort study involving 421 physicians throughout Germany. The analysis includes 2,347 patients with untreated chronic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cohort Studies
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Germany

Share to Hepacivirus

Share to Hepatitis C

Source

Open in PubMed Open full text

Identifiers

PMID: 25238535
DOI: 10.1371/journal.pone.0107592
PMCID: PMC4169557

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predictive factors for sustained virological response after treatment with pegylated interferon α-2a and ribavirin in patients infected with HCV genotypes 2 and 3.PMID 25238535Read ↗

Hepatitis C Virus: Current and Evolving Treatments for Genotypes 2 and 3.Semantic proximity Read ↗

Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.Semantic proximity Read ↗

A Predictive Model for Selecting Patients with HCV Genotype 3 Chronic Infection with a High Probability of Sustained Virological Response to Peginterferon Alfa-2a/Ribavirin.Semantic proximity Read ↗

Response to treatment with interferon-alpha and ribavirin in patients with chronic Hepatitis C virus genotypes 2 and 3 depends on the degree of hepatic fibrosis.Semantic proximity Read ↗

OPERA: responses to peginterferon and ribavirin therapy in a subgroup of interferon-naïve patients with HIV/HCV genotype 2/3 co-infection in Italy.Semantic proximity Read ↗

Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3.Semantic proximity Read ↗

Do differences exist between chronic hepatitis C genotypes 2 and 3?Semantic proximity Read ↗

The effectiveness of retreatment with peginterferon alfa and ribavirin in patients with chronic viral hepatitis C genotype 2 and 3: a prospective cohort study in Brazil.Semantic proximity Read ↗

Factors That Influence the Virological Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin.Semantic proximity Read ↗

Hepatitis C virus infection: Are there still specific problems with genotype 3?Semantic proximity Read ↗

Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.Semantic proximity Read ↗

Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.